ER-KANG(SZ:300267)2022-12-08 05:36Group 1: Market Demand and Growth - The demand for hard capsules in China reached approximately 250 billion to 300 billion units by the end of 2013, with soft capsules at about 50,000 tons annually [2] - The capsule industry is expected to maintain an annual growth rate of around 15% during the "12th Five-Year Plan" period, resulting in an annual increase of approximately 20 billion capsules [2] Group 2: Research and Standards - The company has participated in the development of over 50 pharmaceutical excipient standards for the 2015 edition of the Pharmacopoeia of China, including various starches and other materials [3] - The public announcement period for the pharmaceutical excipient standards is three months [3] Group 3: Project Investment and Progress - The company invested 504.35 million yuan in the construction of a tapioca starch hollow capsule industrial park, with an expected annual production capacity of 30 billion capsules [3] - The project is progressing smoothly and is on track to meet production targets, barring any weather-related disruptions [3] Group 4: Financial Performance - In the first half of 2014, the revenue from pharmaceutical sucrose products increased by 127.64% compared to the same period last year, while the revenue from injectable sulbenicillin sodium products grew by 71.23% [3] Group 5: Market Feedback - Tapioca starch capsules are more widely accepted by consumers compared to gelatin capsules made from animal sources, appealing to groups such as Muslims, Hindus, and vegetarians [3] - There is growing interest from domestic and international clients regarding the company's starch capsule products [3]